Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb study of dapagliflozin in heart failure with preserved ejection fraction
2018-000802-46Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) comparing Dapagliflozin plus standard of care with Placebo plus standard of care (2 arms). Primary endpoint: Primary composite endpoint of cardiovascular death or worsening heart failure. Started Jun 2018; status: completed.
02
Drugs
dapagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2018-000802-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000802-46.